Reverse Engineering Ketamine for New Antidepressants

Researchers at Weill Cornell Medicine are working to reverse engineer the mechanisms of ketamine to develop new antidepressants that offer long-term relief without the drug’s associated risks. The effort focuses on understanding how the medication rapidly restores brain-cell connections and why those benefits typically fade over time.

Ketamine is currently the only widely tested antidepressant capable of relieving symptoms within hours of administration. This stands in contrast to standard antidepressants, such as Prozac, which often require weeks to become effective. While ketamine is effective for patients who do not respond to traditional treatments, its use is limited by potential addiction and other side effects, often restricting treatment to a single dose or a short series of doses.

The Role of Dendritic Spines

In a study published in the journal Science, researchers led by Dr. Conor Liston examined the medial prefrontal cortex (mPFC), a region of the brain critical for emotion regulation. Using mouse models of depression, the team observed that the onset of depression-like behavior was linked to the loss of dendritic spines—root-like structures on neurons that receive input signals from other cells.

The research found that a single dose of ketamine quickly reversed this loss by prompting the growth of new spines on affected neurons. Some of the specific spines that had been lost were restored, which coincided with the reversal of depression-like behavior in the mice.

“Our findings suggest that interventions aimed at maintaining these new connections could be useful for sustaining ketamine’s antidepressant effects.”

Dr. Conor Liston, associate professor of neuroscience in the Feil Family Brain and Mind Research Institute and associate professor of psychiatry at Weill Cornell Medicine

Despite the rapid recovery, the study noted that most of these newly grown spines disappeared within several days. This suggests that while ketamine can trigger the repair of neural circuits, the brain does not naturally maintain these connections, leading to the eventual return of depressive symptoms.

Circuitry and Rapid Response

The Weill Cornell team also observed that depression-like behavior corresponded to disruptions in the circuits formed by mPFC neurons. In depressed states, the coordinated activity of these neurons became less frequent and involved fewer cells.

Notably, the researchers found that the reversal of these circuit disruptions and the subsequent improvement in behavior occurred just a few hours after treatment. This mirrors the rapid response seen in human patients, though the physical regrowth of dendritic spines occurred on a different timeline than the immediate behavioral shift.

Path Toward New Therapeutics

By identifying the specific molecular and cellular changes ketamine induces, scientists hope to create a new class of medications that mimic these positive effects while avoiding the drug’s psychedelic properties and addictive potential.

The goal is to develop a treatment that not only triggers the growth of new synaptic connections but also preserves them. If these connections can be maintained, the need for frequent repeat dosing of ketamine could be reduced, providing a more stable and sustainable recovery for patients with major depressive disorder.

Ketamine was originally developed in the 1960s as an anesthetic and remains in use in veterinary medicine. Its application as an antidepressant has largely been off label at lower doses, although the U.S. Food and Drug Administration has approved a version of the drug specifically for antidepressant use.